- Home
- WLGS vs VYNE Comparison
WLGS vs VYNE Comparison
Compare WLGS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- VYNE
- Stock Information
- Founded
- WLGS 1981
- VYNE 2003
- Country
- WLGS Hong Kong
- VYNE United States
- Employees
- WLGS N/A
- VYNE N/A
- Industry
- WLGS Engineering & Construction
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- VYNE Health Care
- Exchange
- WLGS Nasdaq
- VYNE Nasdaq
- Market Cap
- WLGS 41.7M
- VYNE 41.9M
- IPO Year
- WLGS 2023
- VYNE 2018
- Fundamental
- Price
- WLGS $2.29
- VYNE $2.61
- Analyst Decision
- WLGS
- VYNE Strong Buy
- Analyst Count
- WLGS 0
- VYNE 2
- Target Price
- WLGS N/A
- VYNE $6.88
- AVG Volume (30 Days)
- WLGS 127.2K
- VYNE 71.5K
- Earning Date
- WLGS 12-24-2024
- VYNE 11-07-2024
- Dividend Yield
- WLGS N/A
- VYNE N/A
- EPS Growth
- WLGS N/A
- VYNE N/A
- EPS
- WLGS N/A
- VYNE N/A
- Revenue
- WLGS $6,825,879.00
- VYNE $493,000.00
- Revenue This Year
- WLGS N/A
- VYNE $28.30
- Revenue Next Year
- WLGS N/A
- VYNE N/A
- P/E Ratio
- WLGS N/A
- VYNE N/A
- Revenue Growth
- WLGS 63.69
- VYNE 39.27
- 52 Week Low
- WLGS $0.44
- VYNE $1.57
- 52 Week High
- WLGS $5.57
- VYNE $3.43
- Technical
- Relative Strength Index (RSI)
- WLGS 38.98
- VYNE 44.45
- Support Level
- WLGS $2.31
- VYNE $2.34
- Resistance Level
- WLGS $3.19
- VYNE $2.69
- Average True Range (ATR)
- WLGS 0.65
- VYNE 0.17
- MACD
- WLGS -0.23
- VYNE -0.03
- Stochastic Oscillator
- WLGS 2.96
- VYNE 30.88
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.